Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma (Nature Cancer, (2023), 4, 9, (1292-1308), 10.1038/s43018-023-00610-2)
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A (2023)
Publication Type: Journal article, Erratum
Publication year: 2023
Journal
Book Volume: 4
Pages Range: 1395-
Journal Issue: 9
DOI: 10.1038/s43018-023-00632-w
Abstract
Correction to: Nature Cancer. Published online 31 July 2023. In the version of this article initially published, the description of the proteomic analysis was incorrectly termed reverse phase protein array (RPPA) instead of liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS). The Figure 3d schematic and Figure 3d,e legends as well as the Extended Data Figure 3 legend have been updated, and the Results section “The IL-17-associated cellular microenvironment in dual ICI” and Methods section “In vivo studies” have been corrected accordingly. The error does not affect the results or conclusions of this article, and we apologize for any confusion this may have caused.
Involved external institutions
Universitätsklinikum Essen
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)
Netherlands (NL)
Novartis AG
Switzerland (CH)
Novartis Institutes for BioMedical Research, Inc.
United States (USA) (US)
Kantonsspital St.Gallen
Switzerland (CH)
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)
Netherlands (NL)
Novartis AG
Switzerland (CH)
Novartis Institutes for BioMedical Research, Inc.
United States (USA) (US)
Kantonsspital St.Gallen
Switzerland (CH)
How to cite
APA:
Váraljai, R., Zimmer, L., Al-Matary, Y., Kaptein, P., Albrecht, L.J., Shannan, B.,... Roesch, A. (2023). Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma (Nature Cancer, (2023), 4, 9, (1292-1308), 10.1038/s43018-023-00610-2). Nature Cancer, 4(9), 1395-. https://doi.org/10.1038/s43018-023-00632-w
MLA:
Váraljai, Renáta, et al. "Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma (Nature Cancer, (2023), 4, 9, (1292-1308), 10.1038/s43018-023-00610-2)." Nature Cancer 4.9 (2023): 1395-.
BibTeX: Download